Pearl River Capital, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Pearl River Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$146.51 - $198.2 $362,758 - $490,743	-2,476 Reduced 63.88%	1,400 $209,000
Q4 2023 Feb 13, 2024	BUY	$151.41 - $196.57 $586,865 - $761,905	3,876 New	3,876 $741,000
Q3 2022 Nov 14, 2022	BUY	$138.54 - $232.0 $45,579 - $76,328	329 Added 12.62%	2,935 $587,000
Q2 2022 Aug 12, 2022	SELL	$120.42 - $169.29 $32,392 - $45,539	-269 Reduced 9.36%	2,606 $380,000
Q1 2022 May 13, 2022	SELL	$127.18 - $173.91 $257,666 - $352,341	-2,026 Reduced 41.34%	2,875 $469,000
Q4 2021 Feb 11, 2022	BUY	$159.56 - $209.29 $782,003 - $1.03 Million	4,901 New	4,901 $831,000
Q1 2021 May 14, 2021	SELL	$126.83 - $175.69 $389,368 - $539,368	-3,070 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$122.97 - $147.0 $205,236 - $245,343	1,669 Added 119.13%	3,070 $399,000
Q3 2020 Nov 13, 2020	SELL	$121.19 - $165.49 $7,150 - $9,763	-59 Reduced 4.04%	1,401 $204,000
Q2 2020 Aug 10, 2020	BUY	$104.21 - $156.44 $152,146 - $228,402	1,460 New	1,460 $216,000

645

109M

1.28M

1.22M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $32.8B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Pearl River Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pearl River Capital, LLC with notifications on news.